Marea Therapeutics Reports Positive Phase 1 Results for MAR002 Acromegaly Treatment
核心洞察
Marea Therapeutics (搜索) announced positive topline Phase 1 results for MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (搜索) for acromegaly (搜索) treatment.
The Phase 1 data demonstrated robust, durable IGF-1 (搜索) suppression supporting potential for biweekly to monthly dosing, with Phase 2/3 study initiation expected mid-2026.
The company also highlighted progress on MAR001, its lead cardiometabolic program targeting ANGPTL4 (搜索) for atherosclerotic cardiovascular disease (搜索), with Phase 2b enrollment nearing completion.
Marea Therapeutics (搜索) announced positive topline results from its first-in-human Phase 1 study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (搜索) (GHR) for the treatment of acromegaly (搜索). The clinical-stage biotechnology company, which harnesses advances in human genetics to develop next-generation medicines for cardioendocrine diseases, reported that the data demonstrate proof-of-mechanism and support the therapy's best-in-disease potential.
MAR002 Shows Promise for Convenient Dosing Schedule
The Phase 1 data revealed robust, durable IGF-1 (搜索) suppression that supports potential for biweekly to monthly dosing, a significant advantage for patients with acromegaly (搜索). This dosing profile could represent a substantial improvement over current treatment options for this rare endocrine disorder. The company expects to initiate Phase 2/3 studies for MAR002 in mid-2026.
"The MAR002 data provide clear proof-of-mechanism and underscore our ability to translate human genetic insights into highly differentiated clinical candidates," said Josh Lehrer, M.D., chief executive officer of Marea Therapeutics (搜索).
Broader Pipeline Progress
Beyond MAR002, Marea highlighted significant progress across its cardioendocrine pipeline. The company's lead cardiometabolic program, MAR001, is nearing completion of enrollment in its Phase 2b TYDAL-TIMI 78 study. MAR001 is a first-in-class, subcutaneously delivered monoclonal antibody designed to block the activity of ANGPTL4 (搜索), a genetically validated driver of remnant cholesterol and atherosclerotic cardiovascular disease (搜索) (ASCVD) risk.
Multiple data readouts for MAR001 are expected throughout 2026, and the company is advancing a half-life-extended version, MAR001-HLE (搜索), designed for infrequent, low-volume subcutaneous dosing toward Phase 3 readiness.
Expanding siRNA Platform
Marea is also advancing its next-generation siRNA portfolio, with development candidate nomination(s) expected in 2026. This expansion represents the company's commitment to leveraging multiple therapeutic modalities to address cardioendocrine diseases.
2026 Outlook
"With MAR002 moving toward a registrational study, MAR001 nearing a major Phase 2b readout, and our siRNA platform expanding, Marea is uniquely positioned to redefine the treatment of cardioendocrine diseases. 2026 will be a catalyst-rich year as we execute across our entire portfolio," Lehrer stated.
The company's management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, at 10:30 a.m. PT, where they will likely provide additional details on their clinical programs and strategic direction.